Basal Ganglia
BASAL GANGLIA
Involved in motor system control.
Comprises upper and lower motor neurons and their tracts.
STRUCTURE OF BASAL GANGLIA
Components:
Lentiform Nucleus:
Putamen
Globus Pallidus (II and I)
Caudate Nucleus:
Head (lateral wall of anterior horn of lateral ventricle)
Body (floor of body of lateral ventricle)
Tail (roof of inferior horn of lateral ventricle, ends in the amygdala)
Other Structures:
Subthalamic Nucleus
Substantia Nigra
Pars Compacta
Pars Reticulata
Corpus Striatum:
Caudate Nucleus and Lentiform Nucleus
Ventral Striatum:
Head of Caudate Nucleus and Putamen
Nucleus Accumbens
DOPAMINERGIC PATHWAYS
Nigrostriatal: Substantia Nigra pars compacta to Basal Ganglia
Mesolimbic: Ventral Tegmental Area to Parahippocampal Gyrus and Nucleus Accumbens
Mesocortical: Substantia Nigra pars compacta and VTA to Prefrontal Cortex
BRAIN PATHWAYS TO AND FROM BASAL GANGLIA
Direct Pathway:
Cerebral cortex projects to striatum (caudate + putamen) with glutamatergic fibers.
Substantia Nigra pars compacta excites striatum via dopaminergic fibers.
Striatum uses acetylcholinergic interneurons; projects GABAergic neurons to GPI and SNr.
GPI inhibits thalamus less, thus thalamus gets excited, leading to motor cortex excitation and movement initiation.
Indirect Pathway:
Cortex excites striatum; dopaminergic fibers from SNpc inhibit.
Striatum projects GABAergic fibers to GPII.
GPII inhibits GABAergic fibers to Subthalamic Nucleus.
Excitation of GPI and SNpr inhibit thalamic nuclei (VA and VL), decreasing motor cortex activation and leading to movement inhibition.
BASAL GANGLIA DISORDERS
Hypokinetic Disorders:
Breakdown of the direct pathway
Symptoms: akinesia, bradykinesia
Hyperkinetic Disorders:
Breakdown of the indirect pathway
Symptoms: dyskinesias, chorea, ballismus, athetosis, dystonia
SPECIFIC DISORDERS
Parkinson’s Disease:
Caused by dopaminergic cell depletion in Substantia Nigra leading to nigrostriatal circuitry breakdown.
Symptoms: akinesia, bradykinesia, resting tremor, rigidity, flexed posture, shuffling gait, mask-like expression.
Treatment of Parkinson’s Disease:
L-DOPA administration; anticholinergic medications;
Human embryonic dopamine cell transplantation;
Surgical options like pallidotomy and thalamectomies for non-medicinal responders.
Huntington’s Disease:
Autosomal dominant disorder; degeneration of striatum neurons.
Symptoms: chorea, cognitive decline, psychiatric disturbances; life expectancy 15-20 years post onset.
Sydenham’s Chorea:
Transient childhood chorea related to rheumatic fever affecting the striatum.
Athetosis:
Degeneration of globus pallidus; characterized by slow, writhing movements.
Ballism:
Injury to the subthalamic nucleus; results in contralateral involuntary movements.
OTHER DISORDERS
Wilson’s Disease:
Autosomal recessive disorder impacting copper metabolism; leads to liver and basal ganglia degeneration.
Characterized by Kayser-Fleischer rings in corneas.
Dystonia Musculorum Deformans:
Rare hereditary condition linked to lentiform nucleus injury; causes muscle co-contraction.
Focal Dystonias:
Includes conditions like torticollis, blepharospasm, dysphonia, facial spasm, writer’s cramp.